Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study

PURPOSE: To evaluate the safety and efficacy of regorafenib combined with anti-PD-1 antibody sintilimab (rego-sintilimab) as a second-line treatment for advanced hepatocellular carcinoma (HCC). METHODS: This multicenter retrospective study evaluated consecutive patients with advanced HCC who receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jingjun, Guo, Yongjian, Huang, Wensou, Hong, Xiaotao, Quan, Yi, Lin, Liteng, Zhou, Jingwen, Liang, Licong, Zhang, Yaqin, Zhou, Juan, Cai, Mingyue, Zhu, Kangshun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922463/
https://www.ncbi.nlm.nih.gov/pubmed/35300208
http://dx.doi.org/10.2147/JHC.S353956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922463/
https://www.ncbi.nlm.nih.gov/pubmed/35300208
http://dx.doi.org/10.2147/JHC.S353956

Ejemplares similares